The latest research, products, and discoveries from the science industry’s leading companies and company divisions.
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.
NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for cell based assays. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF's technology before introducing the WOLF to early adopters. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts. We are backed by Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures (Highlander Fund and Triton Fund) and other private investors.
Natera® is a rapidly growing genetic testing and diagnostics company with proprietary bioinformatics and molecular technology. Natera's team of PhDs and engineers is dedicated to refining novel molecular genome assays and complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions with best-in-class accuracy and coverage. Natera's goal is to change the management of genetic disease worldwide, giving patients and providers essential health information.
Expertise in Automated Cell Counting and Analysis In 2003, the founders of Nexcelom introduced the CP2, a convenient tool to assist with manual cell counting. According to Dr. Jean Qiu, founder and CTO at Nexcelom, One day a customer at the NIH asked us to 'make counting under the microscope go away.' We invented Cellometer Auto T4 to measure cell concentration and viability. Since then, Nexcelom has expanded the product range to accommodate researchers analyzing small cells, primary cells, and researchers looking to perform cell-based assays. With multiple patents pending, Nexcelom is a clear leader and innovator in the field of image-based cytometry for cell analysis. Proven Performance Thousands of customers, including the top ten pharmaceutical companies, have come to rely on Cellometer instruments for automated cell concentration & viability analysis. The Cellometer has provided a much faster and more accurate method of counting the 100s of samples we need to set up for flow cytometry analysis." - Dr. Janice Pluth, Lawrence Berkeley Laboratory From the large breweries performing yeast fermentation monitoring to specialized pharmaceutical labs analyzing fragile hepatocytes for toxicology studies, researchers in a wide range of industries have integrated Cellometer instruments into their laboratory testing. Dedicated Applications Support Nexcelom is focused on providing novel tools to meet the specific needs of today's researchers. Our applications specialists are in the field with customers every day, analyzing new cell types, validating new cell-based assays, and exploring new therapeutic areas. Through joint application development, we learn from our customers, the experts in their fields, and assist with integration into their current workflows."- Dr. Bo Lin, Director of Applications Development Our experienced technical support and applications specialists are committed to ensuring products work successfully in the customer's hands and are always eager to provide support via the phone, Internet, and on-site visits.
Nicoya is a Canadian biotechnology company specializing in innovative biosensor technology for label-free biomolecular characterization. In their mission to improve human life, they empower researchers with affordable and user-friendly solutions that maximize their access to high-quality data and advance their understanding of human diseases. With their world-class expertise in nanotechnology and microfluidics, Nicoya is now helping hundreds of scientists succeed in over 40 countries. Visit https://nicoyalife.com/ to learn more.